Work

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Year: 2020

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2020-136398

Authors: Erica D. Warlick, Daniel J. Weisdorf, Daniel A. Vallera, Rose Wangen, Dixie Lewis, JoAnn Knox, Martin Schroeder, Martin Felices, Jeffrey S. Miller

Institutions: University of Minnesota, Masonic Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097220233

Cites:

Cited by: 41

Related to: 10